Diamyd Medical fully subscribes to its pro rata share in NextCell Pharma's rights issue

Booking.com

Diamyd Medical invests its pro rata share corresponding to approximately SEK 3.2 million in the associated company NextCell Pharma’s ongoing rights issue, meaning that Diamyd Medical’s book value of the holding in NextCell Pharma after the investment increases from approximately SEK 5.3 million to approximately SEK 8.5 million.
Diamyd Medical is one of the main owners of NextCell Pharma with an ownership of 12.8%. NextCell Pharma is now carrying out a rights issue which, upon full subscription, will provide NextCell with approximately

SEK 24.9 million before issue costs.

“We

Booking.com

Source: Diamyd Medical fully subscribes to its pro rata share in NextCell Pharma's rights issue

Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.